XBiotech is a biopharmaceutical company developing first-in-class antibody therapies. The Company’s lead product candidate inhibits chronic (sterile) inflammation – a condition involved in the progression of many serious and common diseases. The Company has several groundbreaking clinical trial programs in different areas of medicine including dermatology, oncology, diabetes, cachexia and cardiovascular disease.
XBiotech looks to recruit the best and the brightest in the Biotech industry.
05.15.13 - XBiotech Announces Results for its Xilonix™ Treatment of Non-Small Cell Lung Cancer: XBiotech announced today its recent findings for Non-Small Cell Lung Cancer…more
05.01.13 - XBiotech to Present at UBS Global Healthcare Conference: XBiotech announced today that John Simard will present…more
04.24.13 - XBiotech Enrolls First Patient in Phase III Pivotal Trial of Xilonix™: Trial Results to be Submitted For U.S. Marketing Approval…more
03.26.13 - XBiotech Announces Incorporation of Its Wholly Owned Subsidiary XBiotech Japan KK: The creation of the Japanese Company is…more
TOP LINKS
SCIENTIFIC BACKGROUND
FOLLOW US
